Cencora, Inc. (NYSE:COR) Shares Sold by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC cut its holdings in shares of Cencora, Inc. (NYSE:COR) by 2.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,914 shares of the company’s stock after selling 156 shares during the period. OneDigital Investment Advisors LLC’s holdings in Cencora were worth $1,556,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in COR. Metis Global Partners LLC boosted its stake in shares of Cencora by 2.0% during the 3rd quarter. Metis Global Partners LLC now owns 8,719 shares of the company’s stock worth $1,962,000 after acquiring an additional 175 shares in the last quarter. Schrum Private Wealth Management LLC acquired a new position in shares of Cencora in the 3rd quarter valued at $290,000. Oppenheimer & Co. Inc. increased its stake in Cencora by 2.0% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 5,850 shares of the company’s stock worth $1,317,000 after purchasing an additional 115 shares in the last quarter. First Heartland Consultants Inc. raised its holdings in Cencora by 3.6% during the 3rd quarter. First Heartland Consultants Inc. now owns 2,288 shares of the company’s stock worth $515,000 after buying an additional 79 shares during the period. Finally, Prime Capital Investment Advisors LLC lifted its stake in Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after buying an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.80% of the stock is currently owned by insiders.

Cencora Stock Down 1.3 %

COR stock opened at $240.24 on Monday. The firm has a market cap of $47.34 billion, a PE ratio of 31.99, a PEG ratio of 1.60 and a beta of 0.44. Cencora, Inc. has a 1 year low of $194.23 and a 1 year high of $251.56. The company has a fifty day simple moving average of $232.62 and a 200 day simple moving average of $231.03. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is 27.16%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on COR shares. Leerink Partners cut their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. UBS Group increased their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Wells Fargo & Company lifted their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Bank of America reissued a “neutral” rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Evercore ISI lifted their target price on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.